PortfolioRapha Capital Management Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma
PortfolioRapha Capital Management AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference
PortfolioRapha Capital Management Rapha Capital Management Participates in Series C Financing for Poseida Therapeutics, Inc. Led by Novartis Pharmaceuticals
PortfolioRapha Capital Management 3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors
PortfolioRapha Capital Management AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven Altschuler, MD
PortfolioRapha Capital Management AXT107 Restores Healthy, Non-Leaky Vasculature in the Eye by Inhibiting VEGFR2 and Activating Tie2, the Two Clinically Validated Pathways in Diseases of the Retina
PortfolioRapha Capital Management Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks
PortfolioRapha Capital Management Sightly and Horizon Media score over 99% in IAS YouTube brand safety measurement beta
PortfolioRapha Capital Management Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T
